Key Events This Week
27 Jul: Stock surges 6.94% to Rs.2,528.50 on strong buying interest
30 Jul: Hits new 52-week high at Rs.2,669 before closing lower amid mixed quarterly results
31 Jul: Recovers modestly, closing at Rs.2,482.05 (+0.84%)
Aug 07, 03:30 PM
BSE+NSE Vol: 6.15 k

Hester Biosciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 August 2026, providing investors with the most up-to-date insight into the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
27 Jul: Stock surges 6.94% to Rs.2,528.50 on strong buying interest
30 Jul: Hits new 52-week high at Rs.2,669 before closing lower amid mixed quarterly results
31 Jul: Recovers modestly, closing at Rs.2,482.05 (+0.84%)
Hester Biosciences Ltd's latest financial results for Q1 FY27 present a complex picture of the company's performance. The net profit reported was ₹96.98 crores, reflecting a substantial year-on-year growth of 489.90%. However, this impressive profit figure is accompanied by a concerning decline in net sales, which totaled ₹77.24 crores, representing an 8.17% decrease compared to the same quarter last year. This decline raises questions about the company's revenue generation capabilities and potential market challenges. The operating margin, excluding other income, stood at 29.48%, which shows a slight improvement from the previous year. This indicates that the company has managed to maintain its operating profitability despite the drop in sales, suggesting effective cost management. However, the sequential decline in sales of 22.84% from the previous quarter indicates potential operational challenges that ...
Read full news article
Hester Biosciences Ltd., one of India's pioneering animal healthcare companies, has reported a remarkable 489.90% year-on-year surge in consolidated net profit to ₹96.98 crores for Q1 FY27, driven by an extraordinary one-time gain that inflated pre-tax profit to ₹101.68 crores. However, the underlying operational picture reveals concerning trends, with net sales declining 8.17% year-on-year to ₹77.24 crores and falling 22.84% sequentially from Q4 FY26's ₹100.11 crores. The stock, currently trading at ₹2,461.35 with a market capitalisation of ₹2,137 crores, has declined 1.30% following the results announcement, reflecting investor scepticism about the sustainability of this profit performance.
Read full news article
Hester Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a notable shift from its previously positive growth trajectory. Despite robust profit after tax growth and strong return on capital employed, the company faces headwinds from declining sales and margin contraction, prompting a downgrade in its Mojo Grade from Hold to Sell.
Read full news article
Surging past its previous peaks, Hester Biosciences Ltd touched a fresh 52-week high of Rs 2669 on 30 Jul 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and a market environment where the Sensex trades near its own highs.
Read full news articleThe next results date for Hester Biosciences Ltd is scheduled for 30 July 2026....
Read full news article
Hester Biosciences Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 08 June 2026. While this rating change occurred in early June, the analysis and financial metrics discussed here reflect the company’s current position as of 23 July 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.
Read full news article